Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOG NASDAQ:APLM NASDAQ:CRDF NASDAQ:INDP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$6.19+4.2%$6.08$4.50▼$11.54$129.34M2.3831,210 shs113,212 shsAPLMApollomics$14.28+1.6%$14.91$3.66▼$42.12$30.88M1.537,291 shs21,214 shsCRDFCardiff Oncology$1.90+3.3%$1.69$1.48▼$4.56$125.80M1.36999,979 shs782,719 shsINDPIndaptus Therapeutics$1.76+22.2%$2.05$0.92▼$19.91$163.07M1.3794,197 shs102,221 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition+4.21%+5.81%+5.45%+3.17%-26.57%APLMApollomics+2.65%+0.48%+9.22%-29.34%+114.74%CRDFCardiff Oncology+3.26%+6.74%+17.28%-2.06%-40.44%INDPIndaptus Therapeutics+22.22%+44.26%-39.73%-14.56%-80.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$6.19+4.2%$6.08$4.50▼$11.54$129.34M2.3831,210 shs113,212 shsAPLMApollomics$14.28+1.6%$14.91$3.66▼$42.12$30.88M1.537,291 shs21,214 shsCRDFCardiff Oncology$1.90+3.3%$1.69$1.48▼$4.56$125.80M1.36999,979 shs782,719 shsINDPIndaptus Therapeutics$1.76+22.2%$2.05$0.92▼$19.91$163.07M1.3794,197 shs102,221 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition+4.21%+5.81%+5.45%+3.17%-26.57%APLMApollomics+2.65%+0.48%+9.22%-29.34%+114.74%CRDFCardiff Oncology+3.26%+6.74%+17.28%-2.06%-40.44%INDPIndaptus Therapeutics+22.22%+44.26%-39.73%-14.56%-80.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$14.67136.94% UpsideAPLMApollomics 1.00SellN/AN/ACRDFCardiff Oncology 2.57Moderate Buy$10.10431.58% UpsideINDPIndaptus Therapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest APLM, ACOG, INDP, and CRDF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026ACOGAlpha Cognition Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/22/2026ACOGAlpha Cognition HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.005/18/2026CRDFCardiff Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/14/2026APLMApollomics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026ACOGAlpha Cognition HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.004/21/2026INDPIndaptus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026ACOGAlpha Cognition Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.003/27/2026APLMApollomics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha Cognition$10.22M13.19N/AN/A$2.64 per share2.34APLMApollomics$8.50M3.70N/AN/A($2.89) per share-4.94CRDFCardiff Oncology$525K247.43N/AN/A$0.51 per share3.73INDPIndaptus TherapeuticsN/AN/AN/AN/A$0.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$20.67M-$1.35N/AN/AN/A-232.23%-58.35%-45.99%8/13/2026 (Estimated)APLMApollomics-$10.94MN/AN/AN/AN/AN/AN/AN/AN/ACRDFCardiff Oncology-$45.85M-$0.67N/AN/AN/A-8,527.43%-95.51%-71.47%8/4/2026 (Estimated)INDPIndaptus Therapeutics-$20.85M-$15.40N/AN/AN/AN/A-1,030.07%-299.69%8/17/2026 (Estimated)Latest APLM, ACOG, INDP, and CRDF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026INDPIndaptus Therapeutics-$1.87-$0.23+$1.64-$0.23N/AN/A5/14/2026Q1 2026ACOGAlpha Cognition-$0.41-$0.37+$0.04-$0.32$3.42 million$3.53 million5/14/2026Q1 2026CRDFCardiff Oncology-$0.13-$0.18-$0.05-$0.18$0.09 million$0.04 million3/26/2026Q4 2025ACOGAlpha Cognition-$0.27-$0.30-$0.03-$0.31$4.41 million$2.79 million3/17/2026Q4 2025INDPIndaptus Therapeutics-$4.36-$3.10+$1.26-$3.10N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/AAPLMApollomicsN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A12.6411.52APLMApollomicsN/A0.960.96CRDFCardiff OncologyN/A3.273.27INDPIndaptus TherapeuticsN/A2.342.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/AAPLMApollomics19.13%CRDFCardiff Oncology16.29%INDPIndaptus Therapeutics7.06%Insider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%APLMApollomicsN/ACRDFCardiff Oncology7.70%INDPIndaptus Therapeutics23.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A21.77 million18.73 millionN/AAPLMApollomics452.20 millionN/ANot OptionableCRDFCardiff Oncology2068.37 million63.11 millionOptionableINDPIndaptus Therapeutics6113.24 million86.52 millionNot OptionableAPLM, ACOG, INDP, and CRDF HeadlinesRecent News About These CompaniesIndaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 15, 2026 | globenewswire.comIndaptus Therapeutics Adds Independent Directors Amid Board RefreshApril 23, 2026 | tipranks.comIndaptus Therapeutics Appoints David Natan to BoardJanuary 8, 2026 | tipranks.comBiolojic Design appoints new chief medical officerJanuary 8, 2026 | thepharmaletter.comTIndaptus Therapeutics announces upcoming board leadership transitionJanuary 3, 2026 | msn.comIndaptus Therapeutics enters $6M securities purchase agreement with David LazarDecember 29, 2025 | msn.comIndaptus Therapeutics stock falls after $6 million securities dealDecember 29, 2025 | za.investing.comWhy did INDP stock gain 12% today?December 29, 2025 | msn.comIndaptus Therapeutics Secures $6 Million Investment from David E. Lazar, Appoints Him Co-CEO and ChairmanDecember 29, 2025 | quiverquant.comQIndaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. LazarDecember 29, 2025 | globenewswire.comIndaptus Therapeutics (INDP) Price Target Decreased by 60.00% to 10.20November 17, 2025 | msn.comIndaptus Therapeutics to Present Advances in Allogeneic Immune Cell Therapy at 3rd Donor Selection & Cell Source SummitNovember 17, 2025 | quiverquant.comQIndaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source SummitNovember 17, 2025 | globenewswire.comIndaptus Therapeutics Reports Q3 2025 Financial Results and Corporate UpdateNovember 12, 2025 | quiverquant.comQIndaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateNovember 12, 2025 | globenewswire.comIndaptus Therapeutics (INDP) Price Target Decreased by 86.15% to 25.50October 29, 2025 | msn.comIndaptus Therapeutics stock falls after mixed clinical trial updatesSeptember 6, 2025 | za.investing.comIndaptus Therapeutics provides update on INDP-D101 clinical trialSeptember 5, 2025 | msn.comIndaptus Therapeutics Reports Positive Monotherapy Results for Decoy20 in Urothelial Cancer, Initiates Combination Therapy with TislelizumabSeptember 4, 2025 | quiverquant.comQIndaptus Therapeutics Provides Clinical UpdateSeptember 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPLM, ACOG, INDP, and CRDF Company DescriptionsAlpha Cognition NASDAQ:ACOG$6.19 +0.25 (+4.21%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$6.58 +0.40 (+6.38%) As of 05/29/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Apollomics NASDAQ:APLM$14.28 +0.22 (+1.56%) Closing price 05/29/2026 03:40 PM EasternExtended Trading$14.41 +0.13 (+0.89%) As of 05/29/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.Cardiff Oncology NASDAQ:CRDF$1.90 +0.06 (+3.26%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$1.86 -0.04 (-2.00%) As of 05/29/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Indaptus Therapeutics NASDAQ:INDP$1.76 +0.32 (+22.22%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$1.76 0.00 (0.00%) As of 05/29/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem MongoDB's AI Advantage Is Starting to Show Up in Results Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds These 3 Software Stocks Are Buying Back Shares Hand Over Fist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
